AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization - Additional Indication) from the Drugs Controller General of India for Osimertinib Tablet 40 mg and 80 mg (TagrissoTM) indicated as first-line treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumours have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions mutations.
The receipt of this Import and Market permission paves way for the launch of Osimertinib Tablets (TagrissoTM) for first-line treatment of patients in India, subject to the receipt of other related statutory approvals and licenses.
The first-line use of Osimertinib offers potential new standard of care.
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.1735 as compared to the previous close of Rs. 1710.15. The total number of shares traded during the day was 6483 in over 975 trades.
The stock hit an intraday high of Rs. 1808.85 and intraday low of 1710. The net turnover during the day was Rs. 11391871.